CDKN2A and glioblastoma: Moreover, we will delve deeper into genotyping our model for numerous interests, including CDKN2A deletion [48], EGFR amplification [49], IDH1/2 [50], FGFR-TACC3 [51], and H3K27M mutation [52] because of their prevalence in human glioblastoma.